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journal homepage: ht tp: / /www.elsevier .com/locate/al i tNotes from Japanese Society of AllergologyCelebration of the 50th anniversary of IgE discoveryIgE (gamma E) was discovered by Kimishige and Teruko Ishi-
zaka, who are honorary fellows of Japanese Society of Allergology,
in 1966 as the material identity of reagin (reported in 1921 by
Prausnitz and Kuestner as an internal factor that is present in serum
of atopic patients and can cause skin allergic reaction by antigen
challenge). In 1967, almost at the same time, Johansson and Ben-
nich discovered IgE myeloma (ND myeloma). Then, after conﬁrma-
tion by these investigators, it was ofﬁcially recognized as the new
class of immunoglobulin in 1968.
We, Japanese Society of Allergology, therefore, celebrated the
discovery of IgE on 19th of June, 2016, the last day of 65th Annual
Meeting of the Society, by holding lectures of internationally
outstanding professors, who are closely related to Ishizakas'
research activities, in addition to Prof. Kimishige Ishizaka himself,
who was the ﬁrst speaker (Fig. 1).
Around 1965, almost all people believed that the reagin be-
longs to IgA immunoglobulin class. However, Kimishige Ishizaka,
though he had once reported this theory as well as other investi-
gators, kept investigating other possibilities since there were
several inconsistencies about the theory of reagin to be IgA.
Then, he discovered that reaginic activity of the IgA fraction is
associated with an impurity, which was not detectable by usual
immunochemical methods of 1960's. Thus, they gave up puriﬁca-
tion of reagin, since it was estimated less than 1 mg per mL in
serum of the patients. They switched their strategy to prepare
the rabbit antibodies speciﬁc for reagin, and to identify the reagin
in vitro, by using the rabbit antibodies. Although now every
researcher can conceive it, such a strategy was unprecedented. It
was another Columbus's egg.
After exchanging IgE-containing sera, the Swedish group did not
send their myeloma protein puriﬁed from the ﬁrst patient to Ishiza-
kas anymore, since Pharmacia Company developed Radio-Allergo-
Sorbant-Test and retained its patent. However, the second patient
with IgE myeloma was found in Dartmouth. The patient, Mr. Peter
Shackford generously agreed to give his plasma, and thus Ishizakashttp://dx.doi.org/10.1016/j.alit.2016.08.010
1323-8930/Copyright © 2016, Japanese Society of Allergology. Production and hosting by Else
licenses/by-nc-nd/4.0/).were able to obtain IgE myeloma plasma of more than 30 L until he
passed away.
Ishizakas could monopolize the extremely valuable plasma.
However, they did not do so. In fact, Ishizakas sent the P.S. IgE
over almost all researchers of this ﬁeld upon request without any
conditions, even to their rival researchers who once accused Ishiza-
ka's discovery since they could not reproduce it probably due to
technical immaturity. Then, basophils and mast cells were found
to have receptors for IgE a few years after discovery of IgE. Thus,
almost all the mechanisms involved in the IgE-mediated allergic re-
action were clariﬁed soon after.
The second speaker was Prof. Thomas A.E. Platts-Mills whose
talk's title was “The relevance of IgE antibodies to the diagnosis
and treatment of allergic diseases”. His talk included his recent
discovery of galactose-speciﬁc IgE present in the patients with
the delayed anaphylaxis to red meat (Fig. 2). The third lecture
was given by Prof. Stephen J. Galli and the title was “What
good are mast cells and IgE? They can enhance survival during
innate and acquired host responses to venoms#. He has recently
discovered IgE and mast cells playing a protective role in host de-
fense by efﬁciently destroying venoms (Fig. 3). Then, Prof. Tosh-
iaki Kawakami gave us a lecture about the divergent properties of
IgE molecules. He showed that some IgE molecules can bind to
the histamine-releasing factor and play more enhanced roles in
allergic diseases such as food allergy (Fig. 4). The last speaker
was Prof. Tadamitsu Kishimoto, who discovered IL-6 and isFig. 1. Prof. Kimishige Ishizaka, La Jolla Institute for Allergy and Immunology, USA.
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Fig. 2. Prof. Thomas A.E. Platts-Mills, University of Virginia School of Medicine, USA.
Fig. 3. Prof. Stephen J. Galli, Department of Pathology, Stanford University School of
Medicine, USA.
Fig. 4. Prof. Toshiaki Kawakami, La Jolla Institute for Allergy and Immunology, USA.
Fig. 5. Prof. Tadamitsu Kishimoto, Osaka University Immunology Frontier Research
Center, Japan.
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He succeeded to develop the monoclonal antibody against IL-6
(tocilizumab), which was found extremely safe and effective for
some autoimmune diseases including rheumatoid arthritis
(Fig. 5).
We have drastically decreased the number of fatal asthmatic
patients in the past 50 years by mainly developing inhaled corti-
costeroid drugs and by providing therapeutic guidelines recom-
mending the use of such drugs. However, compared to the effect
of tocilizumab for autoimmune diseases, we seem not to have
such biologics highly effective for many allergic diseases, yet.
This fact suggests that allergic diseases are more complex diseases
than we previously thought. Indeed, whilst IgE-mediated reactions
of allergic diseases were clariﬁed in the past 50 years, non-IgE-
mediated reactions remained unidentiﬁed until recently. Several
genome-wide association studies repeatedly identiﬁed IL-33 as
being a key molecule for asthma and allergies, which trigger pro-
liferation and activation of natural helper cells (group 2 innate
lymphoid cells) which can produce extremely high amount of
type 2 cytokines in the absence of allergen and IgE. All the molec-
ular mechanisms of allergic diseases are expected to be elucidatedsoon. Recent discovery about the important role of skin barrier
dysfunction during infancy on the development of food allergy
and the subsequent allergic diseases (allergic march) as well as
the development of eczema brought us the paradigm shift
regarding the preventative method of allergic diseases starting
at infant period. Safe and inexpensive methods to prevent the
development of allergic diseases, which could be a potential threat
for the next generation, are also highly expected especially
regarding medical economics.Conﬂict of interest
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